

Temporary benefit added to the *Alberta Drug Benefit List (ADBL)*

Due to the unavailability of Mylan-Mirtazapine 15 mg Tablet (DIN 02256096) manufactured by Mylan Pharmaceuticals ULC. and pms-Mirtazapine 15 mg Tablet (DIN 02273942) manufactured by Pharmascience Inc., Sandoz Mirtazapine 15 mg Tablet (DIN 02250594) manufactured by Sandoz Canada Inc. will be considered as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

As of **February 13, 2017**, all claims for Sandoz Mirtazapine 15 mg Tablet (DIN 02250594) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The *ABCDPL* is available online at <https://www.ab.bluecross.ca/providers/pharmacy-home.html>.

If this situation continues to be a long-term matter then this product is subject to the usual review process by the Expert Committee on Drug Evaluation and Therapeutics, and must be approved by the Minister of Health for addition to the *ADBL* in order to remain as a benefit.

Removal of temporary benefit from the *Alberta Drug Benefit List (ADBL)*

Due to the shortage of Apo-Fluconazole-150 150 mg Capsule (DIN 02241895) manufactured by Apotex Inc. and pms-Fluconazole 150 mg Capsule (DIN 02282348) manufactured by Pharmascience Inc., Canesoral 150 mg Capsule (DIN 02311690) manufactured by Bayer Inc. Consumer Care Division was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

Apotex Inc. has advised Alberta Blue Cross that the shortage of Apo-Fluconazole-150 150 mg Capsule (DIN 02241895) has been resolved.

As a result, Canesoral 150 mg Capsule (DIN 02311690) will no longer be considered a temporary benefit for the *ADBL* **after March 17, 2017**.

... continued from previous page

Product supply shortage addressed for the *Alberta Drug Benefit List (ADBL)*

Alberta Blue Cross has been advised by Pharmascience Inc. that the shortage for pms-Desmopressin 0.1 mg Tablet (DIN 02304368) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **March 23, 2017**.

DESMOPRESSIN ACETATE

0.1 MG ORAL TABLET

00002284030	APO-DESMOPRESSIN	APX	\$ 0.3303
00002304368	PMS-DESMOPRESSIN	PMS	\$ 0.3303
00000824305	DDAVP	FEI	\$ 1.3336

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • 403-294-4041 (Calgary and area) • 1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area) • FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefits and supplemental claiming information to assist with the submission of your direct bill drug claims. Visit <https://www.ab.bluecross.ca/providers/pharmacy-home.php>



**The Blue Cross symbol and name are registered marks of the Canadian Association of Blue Cross Plans, an association of independent Blue Cross plans. Licensed to ABC Benefits Corporation for use in operating the Alberta Blue Cross Plan. *† Blue Shield is a registered trade-mark of the Blue Cross Blue Shield Association. ABC 82320.674 2017/02

